BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 7699440)

  • 1. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
    Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
    J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indium-111-pentetreotide in Graves' disease.
    Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
    J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy.
    Kahaly G; Diaz M; Just M; Beyer J; Lieb W
    Thyroid; 1995 Apr; 5(2):107-11. PubMed ID: 7647569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
    Nocaudie M; Bailliez A; Itti E; Bauters C; Wemeau JL; Marchandise X
    Eur J Nucl Med; 1999 May; 26(5):511-7. PubMed ID: 10382096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
    Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
    Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptors in the orbits.
    Durak I; Durak H; Ergin M; Yürekli Y; Kaynak S
    Clin Nucl Med; 1995 Mar; 20(3):237-42. PubMed ID: 7750218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin receptor scintigraphy in thyroid eye disease.
    Kahaly GJ; Förster GJ
    Thyroid; 1998 Jun; 8(6):549-52. PubMed ID: 9669296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
    Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
    Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.
    Förster GJ; Krummenauer F; Nickel O; Kahaly GJ
    Cancer Biother Radiopharm; 2000 Oct; 15(5):517-25. PubMed ID: 11155823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Somatostatin receptor scintigraphy in endocrine orbitopathy].
    Diaz M; Kahaly G; Mühlbach A; Bockisch A; Beyer J; Hahn K
    Rofo; 1994 Dec; 161(6):484-8. PubMed ID: 7803769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
    Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
    Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [[111In]-DTPA-D-phenylalanine octreotide SPECT for the scintigraphic imaging of enhanced somatostatin-receptor density in endocrine ophthalmopathy].
    Cordes M; Hosten N; Gräf KJ; Wenzel KW; Venz S; Keske U; Eichstädt H; Felix R
    Rofo; 1994 Jan; 160(1):11-5. PubMed ID: 8305685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos.
    Mansi L; Rambaldi PF; Bizzarro A; Panza N; Di Martino S; De Bellis A; Del Vecchio E
    Q J Nucl Med; 1995 Jun; 39(2):105-10. PubMed ID: 8574802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
    Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
    Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic indium-111-pentetreotide scintigraphy in breast cancer.
    Bajc M; Ingvar C; Palmer J
    J Nucl Med; 1996 Apr; 37(4):622-6. PubMed ID: 8691252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI.
    Lee JD; Kim DI; Lee JT; Chang JW; Park CY
    J Nucl Med; 1995 Apr; 36(4):537-41. PubMed ID: 7699438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
    Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
    Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indium-111-pentetreotide uptake in endocrine tumors and lymphoma.
    Leners N; Jamar F; Fiasse R; Ferrant A; Pauwels S
    J Nucl Med; 1996 Jun; 37(6):916-22. PubMed ID: 8683311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of octreoscan in thyroid eye disease.
    Krassas GE; Kahaly GJ
    Eur J Endocrinol; 1999 May; 140(5):373-5. PubMed ID: 10229898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.